Rubicon's Generic Nortriptyline Hydrochloride Receives Approval in US
SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel integrin regulating therapies for the treatment of ocular diseases, today announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held virtually May 1-7, 2021.
Enforcement Report - Week of March 24, 2021
Zydus Cadila on Thursday said it has received final approval from the US health regulator to market antidepressant Nortriptyline Hydrochloride capsules.
Enforcement Report - Week of February 10, 2021
Pharma company director disqualified for competition law breaches
The Competition and Markets Authority (CMA) has finally ruled that four pharmaceutical companies - King Pharmaceuticals, Auden Mckenzie, Accord-UK and Alissa Healthcare - have broken the law in relation to the anti-competitive supply of nortriptyline.
IDT Australia release on FDA nod for 23 generics begs the question: Where`s the beef?